Literature DB >> 10391810

Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time.

J K Benedetti1, J Zeh, L Corey.   

Abstract

BACKGROUND: Visits to physicians for genital herpes simplex virus (HSV) infection continue to increase. Most patients with symptomatic infections have recurrences, but no studies of the long-term clinical course of genital herpes are available.
OBJECTIVE: To determine whether the frequency of HSV recurrences decreases over time.
DESIGN: Observational cohort study.
SETTING: University-based research clinic. PATIENTS: 664 persons with genital herpes followed for at least 14 months. MEASUREMENTS: Patients were classified as having initial or recurrent HSV-1 or HSV-2 infection. Patient-reported recurrences and observed recurrences were recorded in a database; more than 12,000 recurrences were analyzed.
RESULTS: Median recurrence rates in the first year of follow-up were one and five per year in patients with newly acquired HSV-1 and HSV-2 infection, respectively; second-year rates were significantly lower in both groups. Patients presenting with recurrent HSV-2 infection had higher rates of recurrence in the first and second years and no significant decrease; significant decreases were detected with longer follow-up. One third of all patients experienced a decrease of two or more recurrences per year between years 1 and 2. Patients infected with HSV-2 who were followed for more than 4 years had a median decrease of two recurrences between years 1 and 5. However, 25% of these patients had an increase of at least one recurrence in year 5, illustrating the variability among HSV-infected persons. Decreases over time among patients who never received suppressive therapy were similar to decreases during untreated periods in patients who received suppressive therapy.
CONCLUSIONS: Herpes simplex virus type 2 infection continues to be a chronic remitting illness. Over time, however, clinically significant reductions occur in a majority of patients. Physicians may wish to periodically assess the need for continued treatment with daily suppressive antiviral chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10391810     DOI: 10.7326/0003-4819-131-1-199907060-00004

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  33 in total

1.  Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV.

Authors:  Darrell H S Tan; Janet M Raboud; Leah Szadkowski; Tae Joon Yi; Brett Shannon; Rupert Kaul; W Conrad Liles; Sharon L Walmsley
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12-17       Impact factor: 2.205

2.  Lower Genital Tract Infections and HIV in Women.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.725

3.  Diagnosis of genital herpes by real time PCR in routine clinical practice.

Authors:  M Ramaswamy; C McDonald; M Smith; D Thomas; S Maxwell; M Tenant-Flowers; A M Geretti
Journal:  Sex Transm Infect       Date:  2004-10       Impact factor: 3.519

4.  Genital herpes.

Authors:  A M Geretti
Journal:  Sex Transm Infect       Date:  2006-12       Impact factor: 3.519

5.  Persistent genital herpes simplex virus-2 shedding years following the first clinical episode.

Authors:  Warren Phipps; Misty Saracino; Amalia Magaret; Stacy Selke; Mike Remington; Meei-Li Huang; Terri Warren; Corey Casper; Lawrence Corey; Anna Wald
Journal:  J Infect Dis       Date:  2010-12-09       Impact factor: 5.226

Review 6.  Using the evidence base on genital herpes: optimising the use of diagnostic tests and information provision.

Authors:  A Scoular
Journal:  Sex Transm Infect       Date:  2002-06       Impact factor: 3.519

7.  Estimating the costs and benefits of screening monogamous, heterosexual couples for unrecognised infection with herpes simplex virus type 2.

Authors:  D N Fisman; E W Hook; S J Goldie
Journal:  Sex Transm Infect       Date:  2003-02       Impact factor: 3.519

8.  Suppressive valacyclovir therapy to reduce genital herpes transmission: good public health policy?

Authors:  Paul E Bonnar
Journal:  Mcgill J Med       Date:  2009-01

9.  Herpes simplex virus type 2 seroprevalence in Korea: rapid increase of HSV-2 seroprevalence in the 30s in the southern part.

Authors:  Haeng Seop Shin; Jeong Joo Park; Chaeshin Chu; Hyeon Je Song; Kyung Soon Cho; Joo Shil Lee; Sung Soon Kim; Mee Kyung Kee
Journal:  J Korean Med Sci       Date:  2007-12       Impact factor: 2.153

10.  Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa.

Authors:  Esther E Freeman; Richard G White; Roel Bakker; Kate K Orroth; Helen A Weiss; Anne Buvé; Richard J Hayes; Judith R Glynn
Journal:  Vaccine       Date:  2008-12-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.